Comparison of S-1–cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials

Hisato Kawakami, Kazumasa Fujitani, Jin Matsuyama, Yusuke Akamaru, Shigeyuki Tamura, Shunji Endo, Yutaka Kimura, Youichi Makari, Takao Tamura, Naotoshi Sugimoto, Daisuke Sakai, Toshimasa Tsujinaka, Masahiro Goto, Yukinori Kurokawa, Toshio Shimokawa, Taroh Satoh, for the Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)　　　　　　　　　　　　　　第18回日本臨床腫瘍学会学術集会（JSMO2021）Virtual Congress 2021.2.18-20